Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01842607
Registration number
NCT01842607
Ethics application status
Date submitted
25/04/2013
Date registered
29/04/2013
Date last updated
6/08/2018
Titles & IDs
Public title
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
Query!
Scientific title
A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in theMEA115588 or MEA115575 Trials
Query!
Secondary ID [1]
0
0
115661
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Mepolizumab
Experimental: Mepolizumab Arm - Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months
Other interventions: Mepolizumab
Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunoglobulin (Ig)E-mediated and Non-allergic) and Local Site Reactions
Query!
Assessment method [1]
0
0
AEs were collected from the Baseline visit until the follow-up visit (approx. 12 weeks post-last dose). Participants were monitored to evaluate the AEs of systemic and local site reaction. AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. On treatment AEs were defined as events occurring from the first dose until 28 days after the last dose of mepolizumab.
Query!
Timepoint [1]
0
0
From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-last dose])
Query!
Secondary outcome [1]
0
0
Number of Participants With Positive Anti-mepolizumab Binding Antibodies and Neutralizing Antibodies (NAb) at the Indicated Time Points
Query!
Assessment method [1]
0
0
Blood samples were collected for the determination of anti-mepolizumab antibodies (ADA) just prior to administration of mepolizumab at indicated time points. Samples that tested positive for anti-mepolizumab antibodies were further tested for the presence of NAb. Participants who switched from the 250 mg vial to the 100 mg vial required one immunogenicity sample prior to the first dose from the 100 mg vial and one sample prior to the second dose from the 100 mg vial at the next visit. The highest value post-baseline visit are based on each participant's highest post-baseline titer. NAb assay result was only presented for participants with positive ADA assay. Highest value post-baseline would be positive for a participant who had both negative and positive post-baseline results.
Query!
Timepoint [1]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [2]
0
0
Annualized Rate of Exacerbations Per Year
Query!
Assessment method [2]
0
0
Exacerbations are defined as the worsening of asthma which requires use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visit. Analysis of the number of exacerbations was performed using a negative binomial model with covariates of region, exacerbations in the year prior to the start of MEA115588 or MEA115575 (as an ordinal variable) and baseline percent (%) predicted forced expiratory volume in 1 second (FEV1), and with logarithm of time on treatment as an offset variable.
Query!
Timepoint [2]
0
0
Baseline up to Exit Visit (approx. 52 weeks) or if Early Withdrawal 4 weeks post last dose
Query!
Secondary outcome [3]
0
0
Mean Change From Baseline in Asthma Control Questionnaire (ACQ) Score
Query!
Assessment method [3]
0
0
The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma control. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, shortness of breath, wheeze). The response options for all these questions consist of a 0 (no impairment/limitation) to 6 (total impairment/ limitation) scale. The overall ACQ score is calculated as the mean of the 5 questions and therefore ranges between 0 (totally controlled) and 6 (severely uncontrolled). The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and Baseline value.
Query!
Timepoint [3]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [4]
0
0
Mean Change From Baseline in Clinic Pre-bronchodilator FEV1 Over the 52-week Treatment Period
Query!
Assessment method [4]
0
0
FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry at Baseline, Week 16, Week 28 and Week 52. Spirometry was performed within ± 1 hour of the Baseline assessment. The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value.
Query!
Timepoint [4]
0
0
From Baseline and up to Week 52
Query!
Secondary outcome [5]
0
0
Number of Participants Withdrawn Due to Lack of Efficacy and Adverse Events From the Study
Query!
Assessment method [5]
0
0
AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.
Query!
Timepoint [5]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [6]
0
0
Number of Participants Hospitalized Due to Exacerbations and Adverse Events
Query!
Assessment method [6]
0
0
AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Exacerbation is defined as worsening of asthma which requires use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visit.
Query!
Timepoint [6]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [7]
0
0
Number of Participants With Systemic (i.e., Allergic/IgE-mediated and Non-allergic) and Local Site Reactions
Query!
Assessment method [7]
0
0
Participants were monitored to evaluate the AEs of systemic and local site reaction. AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Hypersensitivity reactions (i.e., allergic or IgE-mediated reactions) were monitored using the diagnostic criteria for anaphylaxis as outlined by the 2006 Joint NIAID/FAAN Second Symposium on Anaphylaxis. Information was also collected to assess localized site reactions as determined by the investigator. On treatment AEs were defined as events occurring from the first dose until 28 days after the last dose of mepolizumab.
Query!
Timepoint [7]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [8]
0
0
Number of Participants With Electrocardiogram (ECG) Findings at Any Time Post Baseline
Query!
Assessment method [8]
0
0
12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. The ECG was obtained before lung function testing followed by other study procedures. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). ECG findings were summarised at any time post Baseline for participants as normal, abnormal-not clinically significant(A-NCS) and abnormal-clinically significant (A-CS).
Query!
Timepoint [8]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [9]
0
0
Mean Change From Baseline in QT Interval Corrected by Bazett's Method (QTcB) and QT Interval Corrected by Fridericia's Method (QTcF) Values for ECG Assessed at Baseline, Week 28, Week 52 and at Follow-up Visit (Approx. 12 Weeks Post-last Dose)
Query!
Assessment method [9]
0
0
12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. The ECG was obtained before lung function testing followed by other study procedures. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value.
Query!
Timepoint [9]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [10]
0
0
Number of Participants With Maximum Change From Baseline in QTcF Interval for ECG Assessed at Any Time Post Baseline
Query!
Assessment method [10]
0
0
12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). Participants with maximum change (MC) from Baseline were summarised at any time post Baseline for the following categories <-60, >=-60 to <-30, >=-30 to <0, >=0 to <30, >=30 to <60 and >=60. The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value. QTc intervals shown at any time post Baseline are the maximum seen in each participant over the course of the trial.
Query!
Timepoint [10]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [11]
0
0
Number of Participants With Maximum Change From Baseline in QTcB Interval for ECG Assessed at Any Time Post Baseline
Query!
Assessment method [11]
0
0
12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). Participants with maximum change (MC) from Baseline were summarized at any time post Baseline for the following categories <-60, >=-60 to <-30, >=-30 to <0, >=0 to <30, >=30 to <60 and >=60. The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value. QTc intervals shown at any time post Baseline are the maximum seen in each participant over the course of the trial. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Query!
Timepoint [11]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [12]
0
0
Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Assessed at Week 52
Query!
Assessment method [12]
0
0
Vital sign measurements including systolic blood pressure (SBP) and diastolic blood pressure (DBP) were performed at Baseline, at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and follow-up visit (approx. 12 weeks post-last dose). Vital measurements were done pre-injection with the participants sitting, having rested in this position for at least 5 minutes before each reading. They were taken before measurement of any clinic lung function tests or ECGs at the specified time point.
Query!
Timepoint [12]
0
0
Baseline and Week 52
Query!
Secondary outcome [13]
0
0
Change From Baseline in Pulse Rate Assessed at Week 52
Query!
Assessment method [13]
0
0
Vital sign measurements including sitting pulse was performed at Baseline, at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and follow-up visit (approx. 12 weeks post-last dose). Vital measurements were done pre-injection with the participants sitting, having rested in this position for at least 5 minutes before each reading. They were taken before measurement of any clinic lung function tests or ECGs at the specified time point.
Query!
Timepoint [13]
0
0
Baseline and Week 52
Query!
Secondary outcome [14]
0
0
Number of Participants With Clinical Chemistry Parameters Outside the Normal Range at Any Time Post-baseline
Query!
Assessment method [14]
0
0
Clinical chemistry laboratory parameters included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin, calcium, chloride, cholesterol, creatine kinase, creatinine, direct bilirubin, gamma glutamyl transferase, high density lipoprotein (HDL) cholesterol, indirect bilirubin, low density lipoprotein (LDL) cholesterol, lactate dehydrogenase, phosphate, plasma/serum protein, potassium, serum glucose, sodium, triglycerides, urea, and very low density lipoprotein (VLDL) cholesterol assessed at the indicated time points. Laboratory abnormalities outside the normal range (high and low values) at any time post baseline were presented. Any time post Baseline = all visits (including scheduled and unscheduled). If participant had given both high and low value at least once then participant is counted under both high and low category for this visit.
Query!
Timepoint [14]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Secondary outcome [15]
0
0
Number of Participants With Haematology Laboratory Parameters Outside the Normal Range at Any Time Post-baseline
Query!
Assessment method [15]
0
0
Haematology laboratory parameters included basophils, basophils/leukocytes, blood erythrocytes, blood leukocytes, eosinophils, eosinophils/leukocytes, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), erythrocytes distribution width (EDW), hematocrit, hemoglobin, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils segmented (NS), neutrophils/leukocytes, platelets, reticulocytes assessed at Baseline, Week 4, Week 16, Week 28, Week 52 and follow-up visit (approx. 12 weeks post-last dose). Hematology abnormalities outside the normal range (high and low values) at any time post baseline were presented. Any time post Baseline is equal to all visits (including scheduled and unscheduled) post Baseline were considered for this visit derivation. If participant had given both high and low value at least once then participant is counted under both high and low category for this visit.
Query!
Timepoint [15]
0
0
From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])
Query!
Eligibility
Key inclusion criteria
- French subjects: In France, a subject will be eligible for inclusion in this study
only if either affiliated to or a beneficiary of a social security category.
- Informed Consent: Prior to commencing any study related activities, subjects must be
able and willing to provide written informed consent.
- MEA115588 or MEA115575 study completion: Completion of the double-blind
investigational product treatment during MEA115588 or MEA115575.
- Current Anti-Asthma Therapy: Asthma is currently being treated with a controller
medication (i.e., inhaled corticosteroids [ICS] or other asthma controlled medication)
and the subject has been on a controller medication for the past 12 weeks. Subjects
will be expected to continue controller therapy for the duration of the study.
- Male or eligible female subjects:
- To be eligible for entry into the study, females of childbearing potential must commit
to consistent and correct use of an acceptable method of birth control for the
duration of the trial and for 4 months after the last study drug administration.
- A serum pregnancy test is required of all females at the initial Baseline Visit (Visit
1). In addition, a urine pregnancy test will be performed for all females prior to
enrollment, during each scheduled study visit prior to the injection of
investigational product, and during the Follow-up Visit.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Hypersensitivity: Hypersensitivity reaction related to study medication during the
MEA115588 or MEA115575 that led to patient withdrawal. Subjects who experienced a
localized injection site reaction do not need to be excluded.
- Health Status: Clinically significant change in health status during MEA115588 or
MEA115575 which in the opinion of the investigator would make the subject unsuitable
for participation in this long-term study.
- Malignancy: A current malignancy or malignancy that developed during MEA115588 or
MEA115575 (subjects that had localized carcinoma of the skin which was resected for
cure will not be excluded). [Note for South Korea: Korean subjects with a diagnosis of
malignancy within 5 years are excluded]
- Prior SAE: A study related SAE in MEA115588 or MEA115575 that was assessed as possibly
related to study medication by the investigator.
- Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be enrolled
if they plan to become pregnant during the time of study participation.
- ECG: Baseline ECG which has a clinically significant abnormality or which shows
corrected QT interval with Fridericia (QTcF) >=450 millisecond (msec) or QTcF >=480
msec for subjects with Bundle Branch Block.
- Smoking status: Current smokers
- Liver Function: Liver function tests that meet any of the following during one of the
last treatment visits in MEA115588 or MEA115575 : alanine transaminase (ALT) >=2 x
upper limit of normal (ULN); aspartate transaminase (AST) >=2 x ULN; alkaline
phosphatase >=2 x ULN; Bilirubin >1.5 x ULN (isolated bilirubin >1.5 x ULN is
acceptable if bilirubin is fractionated and direct bilirubin is <35%
- Hepatitis Status: Positive Hepatitis B Surface Antigen (HBsAg) screen at Visit 1
- ECG Over-read: Clinically significant abnormality identified during the central
over-read during one of the last treatment visits in MEA115588 or MEA115575
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/05/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
13/03/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
651
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - New Lambton
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Bedford Park
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Clayton
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2310 - New Lambton
Query!
Recruitment postcode(s) [2]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Utah
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Buenos Aires
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Mendoza
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Santa Fe
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Ciudad Autónoma de Buenos Aires
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Bruxelles
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Gent
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Leuven
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Liège
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Alberta
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
British Columbia
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Manitoba
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
Chile
Query!
State/province [26]
0
0
Reg Del Libert Bern Ohiggins
Query!
Country [27]
0
0
Chile
Query!
State/province [27]
0
0
Santiago
Query!
Country [28]
0
0
Chile
Query!
State/province [28]
0
0
Talcahuano
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Brno
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Olomouc
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Praha 4
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Praha 8
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Gières
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Le Kremlin-Bicêtre Cedex
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Lille cedex
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Lyon cedex 04
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Marseille cedex 20
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Montpellier cedex 5
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Nantes cedex 1
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Paris Cedex 18
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Perpignan
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Strasbourg
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Bayern
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Brandenburg
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Hessen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Niedersachsen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Rheinland-Pfalz
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Sachsen-Anhalt
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Schleswig-Holstein
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Berlin
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Hamburg
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Campania
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Emilia-Romagna
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Liguria
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Puglia
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Toscana
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Umbria
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Veneto
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Chiba
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Fukuoka
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Gunma
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Hiroshima
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Hokkaido
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Hyogo
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Ibaraki
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Kanagawa
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Mie
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Okinawa
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Osaka
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Tokyo
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Anyang-Si
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Bucheon-si,
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Cheongju, Chungcheongbuk-do
Query!
Country [74]
0
0
Korea, Republic of
Query!
State/province [74]
0
0
Daegu
Query!
Country [75]
0
0
Korea, Republic of
Query!
State/province [75]
0
0
Donggu Gwangju
Query!
Country [76]
0
0
Korea, Republic of
Query!
State/province [76]
0
0
Incheon
Query!
Country [77]
0
0
Korea, Republic of
Query!
State/province [77]
0
0
Kangwon-do
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Seoul
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Suwon, Kyonggi-do
Query!
Country [80]
0
0
Mexico
Query!
State/province [80]
0
0
Jalisco
Query!
Country [81]
0
0
Mexico
Query!
State/province [81]
0
0
Nuevo León
Query!
Country [82]
0
0
Netherlands
Query!
State/province [82]
0
0
Amsterdam
Query!
Country [83]
0
0
Netherlands
Query!
State/province [83]
0
0
Leeuwarden
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Bialystok
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Krakow
Query!
Country [86]
0
0
Russian Federation
Query!
State/province [86]
0
0
Chelyabinsk
Query!
Country [87]
0
0
Russian Federation
Query!
State/province [87]
0
0
Moscow
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Saint-Petersburg
Query!
Country [89]
0
0
Russian Federation
Query!
State/province [89]
0
0
St. Petersburg
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Alicante
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Barcelona
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Pozuelo De Alarcón/Madrid
Query!
Country [93]
0
0
Ukraine
Query!
State/province [93]
0
0
Kharkiv
Query!
Country [94]
0
0
Ukraine
Query!
State/province [94]
0
0
Kyiv
Query!
Country [95]
0
0
Ukraine
Query!
State/province [95]
0
0
Mykolayiv
Query!
Country [96]
0
0
Ukraine
Query!
State/province [96]
0
0
Vinnytsia
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Leicestershire
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Bradford
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Liverpool
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
London
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Newcastle Upon Tyne
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Plymouth
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab
administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care
in subjects who have severe, refractory asthma and a history of eosinophilic inflammation.
Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to
consent for this study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01842607
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01842607
Download to PDF